Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2014 and presents the new breakdown of its share capital pursuant to the capital increase with preferential subscription rights completed in March 2014.

Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding

Paris, France | Posted on May 12th, 2014

Activity

The revenue recorded by NANOBIOTIX during the first quarter of 2014 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract. This licensing contract was signed with PharmaEngine in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The total upfront payment totaled €810,640 and is apportioned using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region which is anticipated as 2017.

During the quarter, the most significant event has been a capital increase with preferential subscription rights. The subscription ratio was 3 new shares for 14 existing shares at a subscription price of €10.60 per share. The capital increase was successfully completed on 20 March 2014 and the total amount raised was €28.1 million, after full exercise of the extension clause. The settlement-delivery and the trading of the new shares occurred on 24 March 2014. The rationale for raising these funds was mainly to support the acceleration of the product pipeline.

The company believes that the coming year is going to be a pivotal one for its development, in particular with respect to operational and clinical progress.

New composition of Nanobiotix shareholding structure following the capital increase which took place in March 2014

Following the completion of the capital increase, the original institutional shareholders remaining invested in the company represent 30.2% of its capital. A great number of new shareholders have acquired shares, with a significant increase of retail shareholders (43.6% of the capital against 13.1% previously), and with the arrival of a large number of foreign (non-French) institutional investors (79 shareholders representing 10.7% of the capital compared to 2% previously) mainly from Belgium, the Netherlands, Luxemburg and Italy.

Although the capital increase has resulted in an increase in the number of French institutional investors (from 4 to 30), their aggregate proportion decreased from 15% to 8.2%.

In total, institutional investors represent 49.1% of the capital.

Next financial press release: revenue for the second quarter of 2014, on July 11, 2014

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55



NewCap.
Financial communication and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/


Instinctif Partners
Media relations (Outside France)
Melanie Toyne Sewell / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A big nano boost for solar cells: Kyoto University and Osaka Gas effort doubles current efficiencies January 21st, 2017

A toolkit for transformable materials: How to design materials with reprogrammable shape and function January 20th, 2017

Explaining how 2-D materials break at the atomic level January 20th, 2017

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Nanomedicine

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Chemists Cook up New Nanomaterial and Imaging Method: Nanomaterials can store all kinds of things, including energy, drugs and other cargo January 19th, 2017

'5-D protein fingerprinting' could give insights into Alzheimer's, Parkinson's January 19th, 2017

New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017

Announcements

A big nano boost for solar cells: Kyoto University and Osaka Gas effort doubles current efficiencies January 21st, 2017

A toolkit for transformable materials: How to design materials with reprogrammable shape and function January 20th, 2017

New research helps to meet the challenges of nanotechnology: Research helps to make the most of nanoscale catalytic effects for nanotechnology January 20th, 2017

Ultra-precise chip-scale sensor detects unprecedentedly small changes at the nanoscale January 20th, 2017

Financial Reports

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project